Model I-2 (n = 4) and -5 (n = 4) were directly injected with 50 mg of the human AE1-targeted siRNAexpressing vector and 50 mg of the scramble vector into the tail vein, respectively, once every 3 days for a total of seven doses, as described previously (Garg et al., 2008).